Andrew Dickinson - Gilead Sciences President
| GILD Stock | USD 111.53 0.50 0.45% |
President
Mr. Andrew Dickinson is Executive Vice President Corporationrationrate Development and Strategy of the Company. Mr. Dickinson joined Gilead in 2016 as Senior Vice President, Corporationrationrate Development. He led the acquisitions of Kite Pharma, Inc. and Cell Design Labs, Inc., and was instrumental in reshaping Gilead approach to corporate development, increasing the volume and types of agreements that the company has entered into during his tenure. Prior to joining Gilead, Mr. Dickinson served as Global CoHead of Healthcare Investment Banking for Lazard. At Lazard, he advised on numerous, industrydefining merger and acquisition transactions, as well as many other strategic matters across the biopharmaceutical industry since 2018.
| Age | 55 |
| Tenure | 7 years |
| Address | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Andrew Dickinson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Dickinson against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Andrew Dickinson insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Dickinson over six months ago Disposition of 3025 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.1122 % which means that it generated a profit of $0.1122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0229 %, meaning that it created $0.0229 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.20, whereas Return On Capital Employed is forecasted to decline to 0.08. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.8 B, whereas Other Assets are forecasted to decline to about 1.1 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Rady Johnson | Pfizer Inc | 63 | |
| Jennifer Zachary | Merck Company | 46 | |
| Esteban Santos | Amgen Inc | 57 | |
| Jonathan Graham | Amgen Inc | 63 | |
| Anne White | Eli Lilly and | 55 | |
| Jeffrey Stewart | AbbVie Inc | 55 | |
| Daniel Skovronsky | Eli Lilly and | 47 | |
| Julie Gerberding | Merck Company | 64 | |
| Jasmina Brooks | Johnson Johnson | N/A | |
| Adam Dubow | Bristol Myers Squibb | 53 | |
| Franklin Clyburn | Merck Company | 56 | |
| Michael Nally | Merck Company | 44 | |
| Richard DeLuca | Merck Company | 62 | |
| Murdo Gordon | Amgen Inc | 58 | |
| Menelas Pangalos | AstraZeneca PLC ADR | 57 | |
| Leigh Pusey | Eli Lilly and | 61 | |
| Aarti Shah | Eli Lilly and | 55 | |
| Samit Hirawat | Bristol Myers Squibb | 52 | |
| John Young | Pfizer Inc | 59 | |
| Michael Sneed | Johnson Johnson | 60 | |
| Jose Baselga | AstraZeneca PLC ADR | 58 | |
Management Performance
| Return On Equity | 0.0229 | ||||
| Return On Asset | 0.11 |
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Tijerina, Clinical Manufacturing | ||
| SeeChun MD, VP Oncology | ||
| Johanna Mercier, Chief Commercial Officer | ||
| Jyoti Mehra, Executive Vice President of Human Resources | ||
| Bilal Piperdi, Vice Oncology | ||
| Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
| Jackson Egen, Vice Oncology | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, Innovation Research | ||
| Daniel ODay, Chairman of the Board, CEO | ||
| Deborah Telman, General Affairs | ||
| Deborah JD, General Affairs | ||
| Giri Ramsingh, Senior Director | ||
| Jacquie CFA, Vice Relations | ||
| Diane Wilfong, Corp VP | ||
| Flavius MD, Executive Research | ||
| Sandra Patterson, Corporate VP | ||
| Rudolf Ertl, Canada, Australia |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0229 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 156.58 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 89.69 % | ||||
| Number Of Shares Shorted | 22.93 M | ||||
| Price To Earning | 359.42 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.258 | Dividend Share 3.08 | Earnings Share 0.38 | Revenue Per Share | Quarterly Revenue Growth 0.064 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.